2023 updates in metastatic colorectal cancer genomic biomarkers

VJOncology Podcast

VJOncology에서 제공하는 콘텐츠입니다. 에피소드, 그래픽, 팟캐스트 설명을 포함한 모든 팟캐스트 콘텐츠는 VJOncology 또는 해당 팟캐스트 플랫폼 파트너가 직접 업로드하고 제공합니다. 누군가가 귀하의 허락 없이 귀하의 저작물을 사용하고 있다고 생각되는 경우 여기에 설명된 절차를 따르실 수 있습니다 https://ko.player.fm/legal.

11M ago 15:29

MP3•에피소드 홈

Huge advancements in personalized medicine and the availability of genetic testing have led us to consider the use of genomic alterations as biomarkers in cancer treatment. In this podcast, we will revisit the most recent developments in the efficacy and clinical application of genomic biomarkers in metastatic colorectal cancer (mCRC) presented during 2023.

We will hear from Filippo Pietrantonio, MD, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy, regarding the CodeBreak 300 trial (NCT05198934); John H. Strickler, MD, Duke Cancer Institute, Durham, NC, on MOUNTAINEER (NCT03043313); Ardaman Shergill, MD, University of Chicago, Chicago, IL, on PARADIGM (NCT02394795), STRATEGIC-1 (NCT01910610) and CAIRO5 (NCT02162563), and Benny Johnson, DO, The University of Texas MD Anderson Cancer Center, Houston, TX, who rounds off the discussion by considering the use of circulating tumor DNA (ctDNA) to assess minimal residual disease (MRD) status.

Be sure to visit our dedicated page on genomic biomarkers in metastatic colorectal cancer here to learn more about current and future biomarker testing standards, as well as potential treatment directions in the future.

The post 2023 updates in metastatic colorectal cancer genomic biomarkers appeared first on VJOncology.

179 에피소드

#Medicine #Fitness #VJOncology